Evidence map›Paper›PMID 29146721›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.

Mohan S Nandhu, Prajna Behera, Vivek Bhaskaran, Sharon L Longo, Lina M Barrera-Arenas, Sadhak Sengupta, Diego J Rodriguez-Gil, E Antonio Chiocca, Mariano S Viapiano

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Notch signaling pathway: architecture, disease, and therapeutics.Signal transduction and targeted therapy · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mohan S NandhuDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Prajna BeheraDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Vivek BhaskaranDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Sharon L LongoDepartment of Neurosurgery, SUNY Upstate Medical University, Syracuse, New York.
Lina M Barrera-ArenasDepartment of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York.
Sadhak SenguptaBrain Tumor Laboratory, Roger Williams Medical Center, Providence, Rhode Island.
Diego J Rodriguez-GilDepartment of Biomedical Sciences, East Tennessee State University, Johnson City, Tennessee.
E Antonio ChioccaDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Mariano S ViapianoDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. viapianm@upstate.edu.
Brigham and Women's Hospital · USSUNY Upstate Medical University · USEast Tennessee State University · USRoger Williams Medical Center · US

Funding

Targeting the Tumor Matrix as Anti-Invasive and Sensitizing Strategy for GliomaR01CA152065 · NCI · OHIO STATE UNIVERSITY · PI VIAPIANO, MARIANO SEBASTIAN · 2010 to 2014
$1.3M
Chimeric Anti-Fibulin-3 Reagents For Targeted Therapy Of GlioblastomaR21NS091436 · NINDS · UPSTATE MEDICAL UNIVERSITY · PI VIAPIANO, MARIANO SEBASTIAN · 2015 to 2016
$852k
NCI NIH HHS R01 CA152065NINDS NIH HHS R21 NS091436
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Xenograft Model Antitumor AssaysAmino Acid SequenceAnimalsAntibodies, BlockingApoptosisBrain NeoplasmsCell Line, TumorExtracellular Matrix ProteinsGlioblastomaHEK293 CellsHumansMice, Inbred C57BLMice, NudeMolecular Targeted TherapySequence Homology, Amino AcidSignal TransductionAntibodies, BlockingEFEMP1 protein, humanExtracellular Matrix Proteins

Identifiers

PMID29146721
PMCPMC5815892
OpenAlexW2770956706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.